Biohaven Pharmaceutical is eyeing filing for approval early next year for its experimental pain spray after new data showed it hit its primary endpoints in a phase 3 test.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,